A Phase I Study of SHEN26 Capsule in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, and placebo-controlled phase I clinical trial. It is
designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of SHEN26
capsules after single and multiple ascending dosing in healthy Chinese adult participants,
and the food effect on the PK profile of SHEN26 capsules.